ProText Mobility, Inc. (OTCMKTS: TXTM) is running steadily northbound in recent trading and is looking to take out recent highs of $0.0191. TXTM recently proved itself as one of the biggest runners in small caps moving up over 1000% after the Company announced the long awaited RSAMMD reverse merger when RSA Medical Marijuana Dispensaries RSAMMD™ The more we are learning about RSA Medical Marijuana Dispensaries RSAMMD™ the more interesting it becomes. RSAMMD in Joint Venture with Leeds Boerdery, cultivated hemp and cannabis crops this past season on a combined 1000+ hectares. According to RSAMMD website they produced 35,000 kilograms on 1,000 hectares plot sitting on a 5,000-hectare farm so there is lots of room for expansion. They could also greatly increase their yield per hectare as compared to many Companies that can easily get 1,000 kilos per hectare. Currently trading at a $71 million market valuation TXTM has a lot of room to grow.
RSAMMD run by CEO Dylon Du Plooy has a lot going on behind the scenes. In August TXTM provided a shareholder update in which CEO Dylon Du Plooy explained how the Company got the Kettles next generation live plant extraction equipment back to the Company’s 5000 Hectare New Castle Farm. Management envisions commercializing this extraction technology for its own purposes, as well as, for potential global licensing. According to Dylon Du Plooy: “Our investigations have conclusively demonstrated that full-spectrum cannabinoids can be extracted using the proprietary Kettle system, with minimal metabolic conversion, paving the way for advancement of medical research using non-psychoactive cannabis. What has also intrigued us are the findings from prior research and clinical trials that have shown that the Kettle system, when applied to other medicinal plants, can create an extract that is significantly more bioavailable (10-15x) than a standard extract. This means that our cannabis extract should be more potent while providing a dose that could potentially last up to 24 hours in the bloodstream, which is in-line with prior clinical results using other medicinal plants. Medically, this opens the door to a line of natural pharmaceuticals derived from cannabis but at a fraction of the price and with potentially superior outcomes. From a business perspective, an increase of bioavailability in that magnitude can be a game changer for cultivators as it essentially could increase the net yield by a factor of 10-15x per plant, per acre, per farm.”
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
RSA Medical Marijuana Dispensaries RSAMMD™ is a fully licensed health practitioners, qualified to dispense and prescribe medical cannabis in South Africa. The Company offers superior patient care and 100% Indoor and greenhouse grown cannabis ensuring patients receive clean, safe, and pure medical cannabis products. RSAMMD has 2 commerical licenses, 1 dispensing, importation & prescription license, 2 permits, 1 seed bank cultivar and with an annual production of 35,000 kilograms per year.
In June (reverse merger) Republic of South Africa Medical Marijuana Dispensaries Acquisitions LLC (“RSAMMDA.LLC”) announced it has closed on the acquisition of Protext Mobility, Inc (OTC PINK: TXTM) (A.K.A. Protext Pharma) in a share exchange whereby 100% of capital stock in RSAMMDA.LLC will be exchanged for Preferred Stock in Protext. RSAMMDA.LLC. is a jointly owned company focused on acquistions with two principals, Mr. Dylon Du Plooy and Dr. Ahmed Jamaloodeen (“Dr. J”) who represent the South African business entities of RSAMMD and Leeds Boerdery. RSAMMD is a South African pioneer in the research, cultivation, production and distribution of medical cannabis and cannabinoids. Leeds Boerdery, controlled by Dr. J, owns the 5000 Hectacre New Castle Farm as well as federally issued cannabis and hemp licenses issued by the Government of South Africa. RSAMMD management have taken over the daily operations of Protext headed by Mr. Du Plooy as CEO and Director, and Dr. Jamaloodeen as President and Chairman of the Board.
In August TXTM provided a shareholder update in which CEO Dylon Du Plooy explained how the Company got the Kettles next generation live plant extraction equipment back to the Company’s 5000 Hectare New Castle Farm. Management envisions commercializing this extraction technology for its wn purposes, as well as, for potential global licensing.
TXTM is now significantly closer than it ever has been to commercialization in its history.
Dr. Jamaloodeen commented: “And now, with the acquisition complete Protext has management in place with the knowledge, Government relationships and other, compliance, resources, facilities, biomass, human capital and infrastructure that is invaluable. The Permits we are in possession of allow for Genus Cannabis Sativa import, export, grow & cultivation, research, testing, developing end product for global distribution, all of which are anticipated to be utilized by Protext with the end goal to commercialize the live plant extraction technology and bring superior end products to the global market. Having technology that’s been proven to increase bioavailability by 10-15x greater is Significant and puts us Miles ahead of all competitors. Additional testing is anticipated to be conducted over the next few weeks as we are excited to announce the kettle equipment has arrived back at the farm and Now rests safely in the Laboratory it’s new Home. The testing will focus on maximizing yield as well as testing various strains of Genus Cannabis Sativa. We will also begin conducting the R&D using the New Age Extraction Technology for other Indigenous Plant Flora with medicinal properties.
I feel that the Significance of the Extraction Technology with its 10-15X Bioavailability has been over looked and that is due to the complexity of the science and lack of understanding by the shareholders but in layman’s, terms we stand to produce Natural Plant Base Medicine with 10-15 Times more Bioavailability than current products on the market. As we are focused on the reduction of opioids in the pharmaceutical industry, we look towards the indigenous plant flora for their healing properties and turn back towards natural plant-based medicine from whence it came.
Dr.J continued, “As we previously stated, but worth repeating, we entered into this transaction with Protexs we believe there to be numerous synergies by allowing access to certain assets of our established business’ with Protext as well as commercialize the Protext proprietary live plant extraction technology and processes into our existing Genus Cannabis Sativa infrastructure. Prior to the merger, Protext had collaborated with RSAMMD and Leeds Boerdery, whereby the companies utilized Protext’s proprietary live plant extraction technology along with Kettle extraction equipment to conduct a series of live cannabis extraction testing at New Castle Farm under permits for Genus Cannabis Sativa, with the goal to produce an emulsion rich with cannabinoid but with little to no conversion of THC-A to psychoactive THC. We undertook a series of tests to prove out that the Kettle system and extraction technologies did what they were supposed to do. As part of our previous investigations, various tests were completed using live cannabis flower and leaf, rendered into liquid emulsions supplied by the farm in New Castle. Prior to now, it was hypothecated that processing live Genus Cannabis Sativa under lower temperatures would yield a rich nano-emulsion of phytocannabinoids while retaining the non-psychoactive precursor acid form (THC-A). Our investigations have conclusively demonstrated that full-spectrum cannabinoids can be extracted using the proprietary Kettle system, with minimal metabolic conversion, paving the way for advancement of medical research using non-psychoactive cannabis. What has also intrigued us are the findings from prior research and clinical trials that have shown that the Kettle system, when applied to other medicinal plants, can create an extract that is significantly more bioavailable (10-15x) than a standard extract. This means that our cannabis extract should be more potent while providing a dose that could potentially last up to 24 hours in the bloodstream, which is in-line with prior clinical results using other medicinal plants. Medically, this opens the door to a line of natural pharmaceuticals derived from cannabis but at a fraction of the price and with potentially superior outcomes. From a business perspective, an increase of bioavailability in that magnitude can be a game changer for cultivators as it essentially could increase the net yield by a factor of 10-15x per plant, per acre, per farm.”
“All of this work was made possible through existing permits and Infrastructure to conduct research and testing of Genus cannabis sativa at the New Castle Farm, managed and controlled by Dr.J. We are enthusiastic about commercializing the proprietary extraction technology. By devising a way to extract the phytocannabinoids without metabolic conversion of THC-A, we can retain the entourage effect and the full medical potential of Genus Cannabis Sativa, but without the psychoactive property delivered by THC. We believe what we have now shown is a scientifically important milestone and a technology breakthrough that has global significance and we look forward to taking this to commercialization which may include global licensing opportunities to other grow and extraction facilities around the world, This is the turning point of $TXTM in it’s history thus far ” concluded Protext CEO, Mr. Du Plooy. #LetsGoTXTM
On September 7 TXTM announced its Chairman Dr. Ahmed Jamaloodeen (Dr.J) has received the honor of being appointed as Hemp Production Ambassador. A business engagement program took place last week including governmental officials where Dr. J gave a keynote speech highlighting the priorities of hemp farming including education, job creation, poverty eradication, and zero waste.
Dr.J, Protext Chairman and President, commented “It is with great honor to be appointed Hemp Production Ambassador. As Ambassador, one of my roles is to promote with full autonomy and be fully enabled to build the District into a Cannabis/hemp hub as well as support the following initiatives; job creation, poverty eradication, education, attract foreign investment, foreign direct trade initiatives, government to government for corporate enablement. As part of this, last week I had the distinct honor of presenting at a business engagement program centered on Trade and Investment in collaboration with government and business. Several key points were highlighted to assist towns under the municipality’s oversite including: Help businesses to grow and stay in the community, Identify and support the local business community with capacity-building opportunities, Conducive business environment for service delivery to the community. Community uplifting has always been at the forefront of our mission. It was highlighted that there were numerous projects set to roll out to boost the local economy, exports and increase job opportunities. One of the projects included hemp/cannabis production under an MOU signed with a local hemp farmer.”
“We are pleased to confirm that MOU is with our farm, to be used as a pilot, under our stewardship. The pilot will become a model that is duplicable, replicable, equitable, exportable and an example to show what other provinces and districts could strive for in using cannabis/hemp farming for community uplift, job creation, poverty eradication, education and much more. Hemp is a commodity and a plant that the government is backing to boost the economy due to its potential. While hemp and cannabis flower have many positive medicinal uses, the other parts of the plant have many industrial uses. We believe factories in our District, our country and globally have the opportunity to introduce hemp into their existing product lines. We haven’t even begun to scratch the surface on all the opportunities including new technologies that we are developing using live hemp and cannabis plant for processing, extracting and creating end products that should have 10-15x greater bioavailability. The business case and implications on superior bioavailablity is significant as it relates to lower dosing, and substantial increase in production yield for end products, with lower cost and higher ROI. We believe Newcastle and the District can become a cannabis/hemp hub with Africa Free Trade Zone coming up and we look forward to being the leadership in the process. When we talk about the value of human capital, this appointment as Hemp Production Ambassador along with the recent appointment as the National Commodity Chairperson of the largest agricultural union, Protext will see great benefit that the enablement of these appointments represents for their President and Chairman, as government and union collaboration are essentially now wrapped up all in one for corporate enablement,” concluded Dr. J.
Currently trading at a $71 million market valuation TXTM is the perfect RM runner with a far better share structure than HMBL/TSNP did by far and it’s got power TXTM is moving steadily northbound and is a staple among the top most traded stocks in small caps. TXTM recently proved itself as one of the biggest runners in small caps moving up over 1000% after the Company announced the long awaited RSAMMD reverse merger when RSA Medical Marijuana Dispensaries RSAMMD™ RSAMMD run by CEO Dylon Du Plooy has a lot going on behind the scenes. In August TXTM provided a shareholder update in which CEO Dylon Du Plooy explained how the Company got the Kettles next generation live plant extraction equipment back to the Company’s 5000 Hectare New Castle Farm. Management envisions commercializing this extraction technology for its wn purposes, as well as, for potential global licensing. TXTM is steadily marching towards $0.0191, a break over and TXTM could do something really big on a blue-sky breakout. Microcapdaily will be covering RSAMMD as it happens so make sure you subscribe to Microcapdaily right now so you don’t miss it.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in TXTM either long or short and we have not been compensated for this article.
Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic. The London Clinic is UK’s most renowned independent, private hospital, established 1932 with their Spine Clinic being the first specialist spinal unit based in England back in 1997.
“With a focus on providing the very best healthcare outcomes, The London Clinic is an ideal customer for Aclarion as the company works to deliver the Nociscan solution to physicians and patients around the world,” said John Sutcliffe MD, Neurosurgeon and Founder of London Spine Clinic. “The engagement with Aclarion will allow London Spine Clinic to continue offering the high-quality care our patients have come to expect. Patients need a careful assessment, diagnosis, and understanding of the different treatment options. Aclarion’s innovative Nociscan solution will enable us to objectively assess biomarkers associated with low back pain and enhance the precision of each diagnosis.”
$ACON Aclarion Announces New Engagement with The London Clinic and London Spine Clinic
Aclarion, Inc.’s Nociscan Technology is an innovative medical solution that aims to revolutionize the diagnosis of disc-related conditions. They leverage biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain.
$ACON Watching for volume and run. Aclarion Announces New Engagement with The London Clinic and London Spine Clinic
What’s exciting is its advantages over the current standard of care. It offers a non-invasive approach, ensuring patient comfort and safety. Given it’s non-invasive, that also means 0 pain with 0 radiation (typically associated with traditional discography). The best part is it can seamlessly integrate into standard lumbar MRI protocols, making it a convenient and efficient option for healthcare providers.
To Discover the Inside Scoop on ACON, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
The procedure takes approximately 25-45 minutes, thoroughly evaluating spinal discs without compromising accuracy. Additionally, Nociscan technology offers significant cost savings, with a list price of $1,450, making it an affordable alternative to traditional discograms. Overall, Aclarion, Inc.’s technological advances represent a significant push forward in disc-related diagnostic techniques, prioritizing patient well-being, convenience, and affordability.
They also recently completed a study that spanned two years and involved 78 patients at a single site. The success rate soared to an impressive 85% for patients whose treatment strategy aligned with the disks identified by Nociscan. This represented a remarkable 22% improvement over patients whose treatment strategy did not consider the insights provided by Nociscan.
Aclarion expressed confidence that the results of the trial demonstrate the potential of Nociscan to assist physicians in successfully treating DLBP. Dr. Matthew Gornet, orthopedic surgeon and lead author of the study, enthusiastically endorsed Nociscan, stating, “The two-year surgical outcomes of the clinical trial provide unequivocal evidence of its effectiveness, particularly with regards to the primary endpoint, the Oswestry Disability Index (ODI). I firmly believe that Nociscan has the potential to revolutionize the standard of care and accurately aid all physicians treating chronic low back pain.”
$ACON Watching for volume and run. Aclarion Announces New Engagement with The London Clinic and London Spine Clinic
It is worth noting that although Nociscan was performed on all patients in the study, it was not part of the surgical decision-making process, as highlighted by the company.
The commercial agreement between Aclarion, Inc. and the prestigious London Clinic signifies a significant milestone for both parties, carrying the potential for global recognition, revenue growth, and scalability. By integrating Aclarion’s innovative Nociscan Technology, the London Clinic demonstrates its commitment to delivering cutting-edge healthcare to optimize patient well-being and enhance clinical outcomes. Furthermore, the partnership’s success holds the potential for scaling Nociscan Technology to other institutions and markets, propelling Aclarion, Inc. to become a global leader in non-invasive medical technologies while driving substantial revenue growth.
We will update you on ACON when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Aemetis, Inc. (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the U.S. EPA to generate renewable identification numbers (RINs) under the federal Renewable Fuel Standard. They have six dairy biogas digesters up and running, with a seventh one scheduled to start operating in June 2023.
Aemetis plans to generate multiple sources of revenue from its renewable natural gas. They will sell the gas to replace petroleum diesel in transportation, sell California Low Carbon Fuel Standard credits to fuel blenders who need to meet carbon reduction requirements in California, sell the RINs generated under the federal Renewable Fuel Standard, and benefit from production tax credits starting in 2025 under the Inflation Reduction Act.
They have completed constructing and operating six dairy digesters, a biogas pipeline spanning over 40 miles, a central facility to upgrade biogas to renewable natural gas, and a utility pipeline interconnection unit. The renewable natural gas is injected into the utility gas system and stored underground until Aemetis Biogas obtains carbon intensity (CI) pathway approvals from the California Air Resources Board (CARB) to sell credits under the California Low Carbon Fuel Standard.
$Amtx EPA approved kaboom another winner from rara koko private discord – we know the news and catalyst first stamp now 1025am 5/19/23 alert sent to subscribers cell phone all over the world -super fast super quick. pic.twitter.com/2RVHENSnqd
They have already completed 90 days of renewable natural gas production and data collection required for the CARB approval process. While the final pathway is under review by CARB, Aemetis can use a temporary CI pathway with a value of -150, allowing them to start generating revenue in the third quarter of 2023.
To Discover the Inside Scoop on AMTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Andy Foster, the president of Aemetis Biogas Inc., expressed excitement about the approval of Aemetis Biogas for generating D3 RINs, as it marks a significant milestone towards generating full product revenue. He emphasized that the company’s investments since 2019 have directly reduced greenhouse gas pollution, improved air quality in Central Valley communities, and created jobs. Aemetis is committed to expanding their network of dairy digesters and producing more carbon-negative renewable natural gas to replace petroleum diesel.
The dairy digesters, pipeline project, and biogas-to-RNG facility funding includes grants from the California Department of Food and Agriculture and the California Energy Commission. Aemetis also closed a $25 million long-term financing deal with Greater Commercial Lending last fall, supported by a loan guarantee from the USDA. This project financing has a low fixed interest rate for the first five years and spans over 20 years.
Aemetis has plans to file applications for an additional $100 million of loans from the USDA’s REAP loan program. These funds will support the engineering, permitting, and construction of 31 more dairies. Each loan application will be limited to a maximum of $25 million and carry a 20-year repayment term.
Where could Aemetis, Inc. (NASDAQ: AMTX) be in 5 years?
The company has an ambitious Five Year Plan to generate substantial revenue and reduce air and carbon pollution. The plan projects $2.0 billion in revenues, $496 million in net income, and $682 million in adjusted EBITDA by 2027, with strong compound annual growth rates. Aemetis aims to expand its operations by producing Renewable Natural Gas (RNG), Sustainable Aviation Fuel (SAF), Renewable Diesel fuel (RD), and other low-carbon products. The plan emphasizes the positive financial impact of the Inflation Reduction Act.
(told ya) Aemetis Setting Up For Short Squeeze $AMTX our 1-year price target is $17 to $22 https://t.co/kMxOgQYEk2
The plan highlights the financial benefits of the Inflation Reduction Act, which enables the transfer of tax credits and incentives related to production, projected to improve net income by $341 million in 2027.
The plan also focuses on revenue growth in all product lines, including expanding the dairy RNG business, constructing a renewable jet/diesel plant, implementing carbon sequestration, and improving energy efficiencies.
The company has already achieved significant milestones, such as completing biogas pipeline construction, upgrading facilities for biogas-to-RNG production, and progressing in carbon sequestration and renewable jet/diesel plant development. The company has also secured a biodiesel purchase agreement in India and made strides in constructing a solar microgrid and implementing energy-efficient measures.
We will update you on AMTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
GSI Technology, Inc. (NASDAQ: GSIT) has witnessed a significant surge in its stock price, from $1.62 to $3.84, at the time of writing on Friday, May 12. This represents an impressive 137% increase; the volume has been off the hook. If you look at their historical chart, $GSIT had meager volume, sometimes as low as 300 shares traded in a day. If you do the math, that’s less than $500 worth of shares traded in a day – safe to say it was virtually illiquid.
So what happened, and what drove the stock to trade 50M shares with filings or news releases?
After an in-depth examination, GSI Technology, Inc. appears to have experienced a notable turning point in its market trajectory. The catalyst for this transformation was the company’s prominent feature on Fox News, triggering an exponential dissemination of information across various platforms. It is worth highlighting an intriguing phenomenon that tends to transpire in such circumstances: purchasing shares often induces a ripple effect, encouraging further buying activity.
With Fox News bringing the company into the spotlight and stimulating investor interest, a domino effect occurred among astute day traders who eagerly seized the opportunity to partake in this promising venture. Consequently, the trading volume for GSI Technology, Inc. skyrocketed to unprecedented levels, surpassing all previously recorded thresholds.
$GSIT GSIT +64% this am: Number one pick for AI on stew varney fox business moments ago. Analyst said if your broker recommends Invidia fire them this is the company that could be leader of the world and AI.
This surge in volume stands as a testament to the immense enthusiasm that enveloped the market as traders recognized the tremendous potential inherent in $GSIT. This collective enthusiasm resulted in an extraordinary demonstration of market engagement, reflecting a widespread acknowledgment of the company’s significance and the opportunities it presents.
This development showcases the power of influential media coverage and underscores the intriguing dynamics that can arise when investor sentiment aligns with a compelling market narrative.
To Discover the Inside Scoop on GSIT, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Founded in 1995, GSI Technology Inc. has established itself as a prominent provider of semiconductor memory solutions. The company is focused on introducing new products that capitalize on its core strengths, which include radiation-hardened memory products for extreme environments and Gemini, an advanced processing unit (APU) designed to enhance performance in various artificial intelligence (AI) applications. Headquartered in Sunnyvale, California, GSI Technology operates sales offices in the Americas, Europe, and Asia.
$GSIT been doing this a long time & always makes me laugh NO one wanted GSIT at $1.50 or CASH on hand but killing it at $3.20 $$$
GSI Technology is on the verge of reporting its earnings next week, and the company operates in the storage business, which supports the development of highly efficient AI chips. Traditionally, computing involves separate chips for storage and computation, necessitating frequent data exchange. This process incurs significant power consumption and presents scalability challenges.
To address these limitations, GSI Technology has developed a groundbreaking solution called In-memory processing. This innovation substantially reduces computation time from minutes to seconds, milliseconds, or even microseconds. Notably, it also significantly diminishes power consumption and overall cost of ownership. The key to this improvement lies in the massive parallel data processing offered by GSI’s technology, featuring two million-bit processors per chip compared to thousands found in standard graphic processing units (GPUs). Consequently, the system becomes more scalable, enabling efficient and accelerated AI processing.
By streamlining the computing process and integrating storage and computation on a single chip, GSI Technology aims to revolutionize AI processing. This approach offers notable benefits regarding power efficiency, computational speed, and scalability, making it an attractive solution for a wide range of AI applications.
$GSIT earnings May 16 after the market close. Low volume domestic semi conductor. My favorite sector. I have buys at 1.60 and 1.64
In conclusion, GSI Technology, Inc. is poised to deliver innovative semiconductor memory solutions emphasizing AI chip development. The company aims to reduce computation time, power consumption, and total ownership cost through its In-memory processing technology while significantly improving scalability. With its upcoming earnings report, investors and industry observers will closely watch the company’s progress in the storage business and AI chip development.
We will update you on GSIT when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with GSIT.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.